CD28 and neoplasm: The topical application of anti-FAP CAR-T cells, combined with CD28, ΔCD28, 4-1BB co-stimulatory domains and PD-1 inhibition has been shown to provide transient tumour control and improve the survival in humanized mouse MM models.